arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Xenon Pharmaceuticals Inc.

XENE
$63.44 ▼ -1.08 (-1.67%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
54 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Xenon Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.5B
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -8.2%
FCF / Share $-1.02
Trailing P/E
Price / Book 4.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-102.30M
↓ -57.3%
Operating Margin Operating profit as % of sales
-198.1%
↓ -3.2%
FCF / Share Free cash flow per share
$-1.02
↓ -30.0%
Long-Term Debt Long-term obligations
$10.89M
↓ -7.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
14
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 54 quarters